Cognition Therapeutics Inc (NASDAQ:CGTX) does about 1.08M shares in volume on a normal day but saw 1072288 shares change hands in the recent trading day. The company now has a market cap of 19.47M USD. Its current market price is $0.31, marking an increase of 3.87% compared to the previous close of $0.30. The 52 week high reached by this stock is $2.54 whilst the lowest price level in 52 weeks is $0.22.
The consensus objective for the share price is $3.25, suggesting that the stock has a potential upside of 90.46% over the period.
FactSet Research has provided data showing that 3 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 3 analysts have rated it as a buy and 0 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Strong Buy the stock.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on December 19, 2024 when B. Riley Securities upgraded the stock to “Buy” and issued a price target of between $1 and $1.50. Oppenheimer initiated its price target at $22.
The current price level is 4.33%, -10.27%, and -37.28% away from its SMA20, SMA50, and SMA200 respectively, with the CGTX price moving above the 50-day SMA on current market day. Cognition Therapeutics Inc (CGTX) stock is up 1.32% over the week and 4.28% over the past month. Its price is -55.23% year-to-date and -82.84% over the past year.
To reach the target analysts have set, the stock logically needs to grow 90.46 percent from here.
Outstanding shares total 61.97M with insiders holding 0.59% of the shares and institutional holders owning 18.80% of the company’s common stock. The company has a return on investment of -265.34% and return on equity of -161.93%. The beta has a value of 0.79. Price to book ratio is 1.59.
